You are currently browsing the daily archive for July 12, 2013.
Uppsala, Sweden, July 4, 2013. Orexo Labs announced it has received approval from the F.D.A. for Zubsolv™ (buprenorphine/naloxone) sublingual tablet CIII. Zubsolv is formulated for treatment for people suffering from opioid dependence

YOUR COMMENTS